Study objective: To compare the safety of salmeterol xinafoate or placebo added to usual asthma care. Design: A 28-week, randomized, double-blind, placebo-controlled, observational study.

Introduction: The incidence of asthma exacerbations in patients receiving salmeterol/fluticasone propionate (Seretide™ or Advair ®) is low. However, when asthma control deteriorates ...

Teva to provide two generic inhaler products to Direct Relief for its network of free and charitable clinicsThe program, ...

In this post hoc analysis, data from the TOwards a Revolution in COPD Health (TORCH) study were used to investigate whether use of the long-acting β 2 agonist salmeterol over 3 years increased the ...

Dr Baibing Chen, who is based out of Michigan, says that he sees many patients with tremors. But before evaluating them for ...

Last year saw a key development in the US respiratory diseases market when Mylan finally launched its generic version of GlaxoSmithKline’s blockbuster inhaler Advair (fluticasone+salmeterol).

Her symptoms remained troublesome and she was changed to fluticasone 750 μg twice daily together with inhaled salmeterol 50 μg twice daily via a large volume spacer. Despite this, she remained ...